9Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection,evaluation,and treatment of high blood cholesterol in adults (Adult Treatment Panel Ⅲ)[J].JAMA,2001 ;285:2486-97.
1[1]Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the nation cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol (adult treatment panel Ⅱ). JAMA, 1993, 269:3015.
2[2]Expert Paned on Detection, Evaluation, and treatment of high blood cholesterol in adults. Summary of the third report of the nation cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol (adult treatment panel Ⅲ) .JAMA, 2001, 285(10):2486.
3[4]Gaziano JM. Primary and secondary prevention of coronary heart disease. In: Braunwald E, et al, eds. Heart disease (6th ed). W.B Saunders Company, Philadelphia Pennsylvania (19106), 2001. 1041-1065.
4[5]West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West Scotland coronary prevention study (woscops). Circulation, 1998, 97:1440.
5[6]Pedersen TR, Olsson AG, Fargeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 1998, 97:1446.
6[7]Sacks FM, Pfeffer MA, Moge'L, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels are acute myocardial infarction: the cholesterol and recurrent events trial (CARE). Am J Cardiol, 1991, 68:1436.
7[8]Sacks FM, Moye LA, Davi BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent event trial. Circulation, 1998, 97:1446.
8[9]Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet, 2002, 360: 1623-1630.
9[10]Sever PS, Dahlof B, Poulter NR, et al. Preevention of coronary and stroke events with atorvastatin in hypertensive patients who have averge or lower-than-average cholesterol concentration, in the anglo-scandinavian cardiac outcomes trail-lipid lowering arm (ASCOT-LLA): a muticenter radomised controlled trial. Lancet, 2003, 362:1149-1158.
10[1]National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ ). Third report of the national cholesterol education program (NCEP) expertpanel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ ) final report [J].Circulation, 2002, 106:3 143.
